Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This study is for people with solid tumors cancer for which the standard chemotherapy drugs
have not worked. The purpose of this research is to evaluate the side effects of Xeloda (also
called capecitabine) in combination with a new anticancer agent called Gleevec (also called
imatinib mesylate). Xeloda is an anticancer drug, and can be taken by mouth. The active
ingredient is a well-studied cancer drug called 5-FU. Xeloda is approved by the FDA for the
treatment of colon cancer. Gleevec is approved in the US for the treatment of patients with a
leukemia called CML (increase of white blood cells) after failure of standard therapy. It is
also approved by the FDA for patients with Gastrointestinal Stromal Tumors (a rare tumor in
the digestive tract).
This study will test how much Gleevec we can safely give with Xeloda. Xeloda will be given at
the recommended dose for colorectal cancer and Gleevec will be given in increasing amounts.